Macrolide resistance: An increasing concern for treatment failure in children

Pediatric Infectious Disease Journal

Volumn 22, Issue 8 SUPPL., 2003, Pages

  Jacobs, Michael R ^a   Johnson, Candice E ^a  

^a NONE

Author keywords

Amoxicillin clavulanate; Antimicrobials; Children; Macrolides; Pediatrics; Resistance; Respiratory tract infections

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFACLOR; CEFDINIR; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LINCOSAMIDE; LORACARBEF; MACROLIDE; MIKAMYCIN B; PENICILLIN G; ROXITHROMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIOSTASIS; CLINICAL TRIAL; DAY CARE; DOSE RESPONSE; DRUG CHOICE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TRANSPORT; GEOGRAPHIC DISTRIBUTION; HAEMOPHILUS INFLUENZAE; HUMAN; MORAXELLA CATARRHALIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

EID: 0042236534     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200308001-00004     Document Type: Review

References (66)

1. Pichichero ME. Resistant respiratory pathogens and extended-spectrum antibiotics. Am Fam Physician 1995;52:1739-46.
2. Ruoff G. Upper respiratory tract infections in family practice. Pediatr Infect Dis J 1998;17:S73-8.
3. Pelton SI. Otitis media. In: Long SS, Pickering LK, Prober CG, eds. Principles and practice of pediatric infectious diseases. 2nd ed. chap 27. Philadelphia: Churchill Livingstone, 2003.
4. Bluestone CD, Klein JO. Otitis media in infants and children. 3rd ed. St Louis: Harcourt Health Sciences Group, 2000.
5. Hoberman A, Marchant CD, Kaplan SL, Feldman S. Treatment of acute otitis media consensus recommendations, Clin Pediatr 2002;41:373-90.
6. Guay DRP. Macrolide antibiotics in paediatric infectious diseases. Drugs 1996;51:515-36.
7. Klein JO. History of macrolide use in pediatrics. Pediatr Infect Dis J 1997;16:427-31.
8. Ghaffar F, Muniz LS, Katz K, et al. Effects of large dosages of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, nonpneumococcal alpha-hemolytic streptococci, and Staphylococcus aureus in children with acute otitis media. Clin Infect Dis 2002;34:1301-9.
9. Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 2001;61:443-98.
10. Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother 1993;31(Suppl C):1-9.
11. Menninger JR, Otto DP. Erythromycin, carbomycin, and spiramycin inhibit protein synthesis by stimulating the dissociation of peptidyl-tRNA from ribosomes. Antimicrob Agents Chemother 1982;21:811-18.
12. Gay K, Baughman W, Miller Y, et al. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis 2000;182:1417-24.
13. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995;39:577-85.
14. Johnston NJ, de Azavedo JC, Kellner JD, Low DE. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998;42:2425-6.
15. Lai CJ, Weisblum B. Altered methylation of ribosomal RNA in an erythromycin-resistant strain of Staphylococcus aureus. Proc Natl Acad Sci USA 1971;68:856-60.
16. Leclercq R, Courvalin P. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob Agents Chemother 1991;35:1273-6.
17. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996;40:1817-24.
18. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000;31:1008-11.
19. Shortridge VD, Flamm RK, Ramer N, Beyer J, Tanaka SK. Novel mechanism of macrolide resistance in Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1996;26:73-8.
20. Butler JC, Lennox JL, McDougal LK, Sutcliffe JA, Tait-Kamradt A, Tenover FC. Macrolide-resistant pneumococcal endocarditis and epidural abscess that develop during erythromycin therapy. Clin Infect Dis 2003;36:e19-25.
21. Musher DM, Dowell ME, Shortridge VD, Jorgensen JH, Le Magueres P, Krause KL. Emergence of macrolide resistance during treatment of pneumococcal pneumonia [Letter]. N Engl J Med 2002;346:630-1.
22. Nagai K, Appelbaum PC, Davies TA, et al. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 central and Eastern European countries. Antimicrob Agents Chemother 2002;46:371-7.
23. Peric M, Bozdogan B, Jacobs MR, Appelbaum PC. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 2003;47:1017-22.
24. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001;7:589-96.
25. Novelli A, Fallani S, Cassetta MI, Arrigucci S, Mazzei T. In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin. J Chemother 2002;14:584-90.
26. Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch GA, Appelbaum PC. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study. Antimicrob Agents Chemother 1999;43:1901-8.
27. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, and the Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:DOI: 10.1093/jac/dkg321.
28. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001;32(Suppl 2):S81-93.
29. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 1999;74:613-34.
30. Kapusnik-Uner JE, Sande MA, Chambers HF. Antimicrobial agents: tetracyclines, chloramphenicol, erythromycin, and miscellaneous antibacterial agents. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilman's The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:1135-40.
31. Blondeau JM, Tillotson GS. Antimicrobial susceptibility patterns of respiratory pathogens: a global perspective. Semin Respir Infect 2000;15:195-207.
32. Jacoby GA. Prevalence and resistance mechanisms of common bacterial respiratory pathogens. Clin Infect Dis 1994;18:951-7.
33. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-53.
34. Dowell SF, Butler JC, Giebink GS, et al., and the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Acute otitis media: management and surveillance in an era of pneumococcal resistance-a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1-9.
35. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J Antimicrob Chemother 2000;46:3-9.
36. Sahm DF, Jones ME, Hickey ML, Diakun DR, Mani SV, Thornsberry C. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J Antimicrob Chemother 2000;45:457-66.
37. Hyde TB, Gay K, Stephens DS, et al., for the Active Bacterial Core Surveillance/Emerging Infections Program Network. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001;286:1857-62.
38. Ringertz S, Kronvall G. Increased use of erythromycin causes resistance in Haemophilus influenzae. Scand J Infect Dis 1987;19:247-56.
39. Cǐzmǎn M, Pokorn M, Seme K, Paragi M, Orazem A. Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens. Eur J Clin Microbiol Infect Dis 1999;18:522-4.
40. Pihlajamäki M, Kotilainen P, Kaurila T, Klaukka T, Palva E, Huovinen P, Finnish Study Group for Antimicrobial Resistance (FiRe Network). Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis 2001;33:483-8.
41. Seppälä H, Klaukka T, Vuopio-Varkila J, et al., and the Finnish Study Group for Antimicrobial Resistance. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997;337:441-6.
42. Arnold KE, Leggiadro RJ, Breiman RF, et al. Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee. J Pediatr 1996;128:757-64.
43. Givon-Lavi N, Dagan R, Fraser D, Yagupsky P, Porat N. Marked differences in pneumococcal carriage and resistance patterns between daycare centers located within a small area. Clin Infect Dis 1999;29:1274-80.
44. Lopez B, Cima MD, Vazquez F, et al. Epidemiological study of Streptococcus pneumoniae carriers in healthy primary-school children. Eur J Clin Microbiol Infect Dis 1999;18:771-6.
45. Melander E, Mölstad S, Persson K, Hansson HB, Söderström M, Ekdahl K. Previous antibiotic consumption and other risk factors for carriage of penicillin-resistant Streptococcus pneumoniae in children. Eur J Clin Microbiol Infect Dis 1998;17:834-8.
46. Syrogiannopoulos GA, Grivea IN, Katopodis GD, Geslin P, Jacobs MR, Beratis NG. Carriage of antibiotic-resistant Streptococcuspneumoniae in Greek infants and toddlers. Eur J Clin Microbiol Infect Dis 2000;19:288-93.
47. Zenni MK, Cheatham SH, Thompson JM, et al. Streptococcus pneumoniae colonization in the young child: association with otitis media and resistance to penicillin. J Pediatr 1995;127:533-7.
48. Kastner U, Guggenbichler JP. Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. Infection 2001;29:251-6.
49. Appelbaum PC, Gladkova C, Hryniewicz W, et al. Carriage of antibiotic-resistant Streptococcus pneumoniae by children in Eastern and Central Europe: a multicenter study with use of standardized methods. Clin Infect Dis 1996;23:712-17.
50. Joloba ML, Bajaksouzian S, Palavecino E, Whalen C, Jacobs MR. High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala, Uganda. Int J Antimicrob Agents 2001;17:395-400.
51. Joloba ML, Windau A, Bajaksouzian S, Appelbaum PC, Hausdorff WP, Jacobs MR. Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. Clin Infect Dis 2001;33:1489-94.
52. Lee NY, Song JH, Kim S, et al. Carriage of antibioticresistant pneumococci among Asian children: a multinational surveillance by the Asian Network for Surveillance of Resistant Pathogens (ANSORP). Clin Infect Dis 2001;32:1463-9.
53. Reichler MR, Allphin AA, Breiman RF, et al. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis 1992;166:1346-53.
54. Ronchetti MP, Merolla A, Bajaksouzian S, Violo G, Ronchetti R, Jacobs MR. Antimicrobial susceptibility of Streptococcus pneumoniae from children attending day-care centers in a central Italian city. Clin Microbiol Infect 1998;4:622-6.
55. Ronchetti MP, Guglielmi F, Latini L, et al. Resistance patterns of Streptococcus pneumoniae from children in central Italy. Eur J Clin Microbiol Infect Dis 1999;18:376-9.
56. Syrogiannopoulos GA, Grivea IN, Beratis NG, et al. Resistance patterns of Streptococcus pneumoniae from carriers attending day-care centers in southwestern Greece. Clin Infect Dis 1997;25:188-94.
57. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-64.
58. Moreno S, García-Leoni ME, Cercenado E, Diaz MD, Bernaldo de Quirós JC, Bouza E. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis 1995;20:1195-200.
59. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin [Letter]. Clin Infect Dis 2000;31:613-5.
60. Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy [Letter]. Chest 2000;118:1839-40.
61. American Academy of Pediatrics. Clinical practice guideline: management of sinusitis. Pediatrics 2001;108:798-808.
62. Dagan R, Johnson CE, Mclinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000;19:95-104.
63. Howie VM, Ploussard JH. Efficacy of fixed combination antibiotics versus separate components in otitis media. Clin Pediatr 1972;11:205-14.
64. Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000;44:43-50.
65. Heffelfinger JD, Dowell SF, Jorgensen JH, et al., and the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-408.
66. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2000;123(Suppl):s1-32.